Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib DR in Non-Small Cell Lung Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib DR in Non-Small Cell Lung Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Vebreltinib DR in Non-Small Cell Lung Cancer Drug Details:
Vebreltinib ER (Vambiru) is a potent, small molecule, orally bioavailable, and highly selective anticancer agent. It is formulated as an enteric-coated capsule for the oral route of administration. Vambiru is indicated to treat first-line, locally advanced or metastatic non-leukemia patients with mesenchymal-to-epithelial transition factor (MET) exon 14 skipping, non-small cell lung cancer (NSCLC). It is also indicated for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. It is also under development for the treatment of intrahepatic bile duct cancer, breast cancer and head and neck cancer.APL-101 (CBT-101) is under development for the treatment of c-Met dysregulation advanced solid tumors such as non-small cell lung cancer, primary CNS tumor, gastric cancer, hepatic cancer, recurrent glioblastoma multiforme, pancreatic cancer, colon cancer, leptomeningeal disease (neoplastic meningitis, leptomeningeal carcinomatosis), esophageal cancer, glioblastoma multiforme. The therapeutic candidate is administered orally as a enteric coated capsule. It acts by targeting the c-Met (hepatocyte growth factor receptor). It was also under development for the treatment of advanced or metastatic hepatocellular carcinoma, high-grade gliomas, gastric cancer, gastroesophageal junction adenocarcinoma, renal cell carcinoma,.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Vebreltinib DR LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports